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ABSTRACT 
 
This thesis describes an optical homogeneous assay that uses the enzyme reconstitution 
reaction of the prosthetic group pyrroloquinoline quinone (PQQ) with apo-glucose 
dehydrogenase (apo-GDH) for the detection of bilayer membrane permeabilization by 
antimicrobial peptides, synthetic copolymers, and complement fixation.  Liposomes, small 
spheres made of lipid bilayers, are employed to encapsulate PQQ as a tracer.  When PQQ is 
released through the bilayers of the liposomes by a given species, it binds to apo-GDH and 
activates the catalytic center.  PQQ acts as a redox center in this enzyme, catalyzing the 
oxidation of glucose to glucono lactone. A redox dye, dichlorophenol indophenol (DCPIP) is 
introduced to the assay mixture, which changes color from blue in its oxidized form to colorless 
when reduced by PQQ.  The color change due to the reduction of DCPIP is measured via an 
optical absorbance assay. 
PQQ-loaded liposomes and a membrane permeabilizing agent are added to the wells of a 
microtiter plate.  The concentration of peptide or polymer alters the rate of membrane 
permeabilization, releasing PQQ, which is detected by the DCPIP color change.  For quantitative 
measurements, the absorbance change over a 30 min time period was measured.  This 
absorbance change is related to the relative membrane permeabilizing activity and concentration 
of the antimicrobial agent.  By varying the liposome composition, both the antimicrobial activity 
and the potential toxicity towards mammalian cells of these agents can be evaluated.   
This thesis also discusses the potential adaption of the absorbance-based PQQ assay to 
combine with complement fixation to develop a diagnostic assay for heparin-induced 
thrombocytopenia (HIT).  A model system using liposomes with a 2,4–dinitrophenyl (DNP) 
containing lipid is used as an initial model.  The DNP molecules are present on the surface of the 
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liposomes, and therefore should complex to anti-DNP antibodies in solution.  The addition of 
complement in the presence of anti-DNP should result in liposome lysis, while addition without 
anti-DNP should not cause liposome lysis. 
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INTRODUCTION 
 
Antibacterial Resistance 
Since A. Fleming’s discovery of the antibacterial activity of penicillin in 19291, antibiotics 
have become standard in the treatment of bacterial infection.  Recently, however, antibacterial 
resistance has grown, due to both the evolution of bacterial strains and the misuse of antibiotics, 
resulting in a class of bacterial infections that cannot be treated by traditional antibiotics.  
Because of this resistance, there is a growing need for the development of new antimicrobial 
therapeutic agents. 
 
 Antimicrobial Peptides 
One type of new therapeutic agents being developed is antimicrobial peptides
2
.  
Antimicrobial peptides are naturally present in the immune systems of various organisms
3
, 
functioning as a natural defense mechanism by killing foreign cells.  When found in nature, the 
sequences of antimicrobial peptides are so diverse that the same sequence is rarely found in 
multiple species of animals; the diversity of these peptides is enhanced by synthetic manufacture 
in laboratories.  Despite this diversity, however, antimicrobial peptides are almost all composed 
of hydrophilic, hydrophobic, and cationic amino acids organized in an amphipathic structure
4
. 
These peptides function by targeting 
foreign microbes and binding to their exterior 
membranes, subsequently permeating the cell 
membrane and destroying the cell.  The 
membrane of the foreign cell is lysed through 
Figure 1: Membrane lysis by antimicrobial peptides. Peptides 
compromise the membrane of the foreign cell by replacing the 
lipids composing the outer layer. 
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interaction with the antimicrobial peptide, which leads to a displacement of the membrane lipids 
and alters the overall membrane structure
4
 (Figure 1).   
The use of antimicrobial peptides as antibacterial therapeutic agents is potentially superior 
to that of traditional antibiotics due to their wide range of antibacterial activity and applicability.  
Furthermore, it has been shown that antimicrobial peptides not only kill bacteria faster than 
antibiotics, but they continue to be effective in fighting bacterial strains already resistant to 
traditional treatments
5
.  As a result of their effectiveness against bacterial infections, synthetic 
antimicrobial peptides are currently being developed, resulting in the need to devise a fast and 
simple method for screening the antimicrobial activity of new peptides on both gram positive and 
gram negative bacteria, as well as the toxicity of new peptides against mammalian cells. 
 
Synthetic Copolymers 
In addition to the work being done with antimicrobial peptides, efforts have been made to 
create synthetic polymers that display similar antimicrobial properties.  The low molecular 
weight copolymers developed by Kuroda et al. have been shown to demonstrate antimicrobial 
activity through a mechanism that involves the disruption of cell membranes
6-7
.  These 
methacrylamide copolymers are comprised of hydrophobic backbones with side chains 
consisting of protonated primary amine groups and hydrophobic alkyl groups.  The 
hydrophobicity of the copolymers is determined by the 
mole fraction of the alkyl side chains (falkyl), as well as 
their length (Figure 2).  Increasing the mole fraction and 
length of the alkyl side chains increases the copolymer’s 
hydrophobicity, which increases the polymer’s 
Figure 2: Base structure of methacrylamide 
random copolymers. R is either butyl (PB series) 
or hexyl (PH series). falkyl is the mole fraction of 
alkyl side chains. 
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antimicrobial activity against Escherichia coli and Staphylococcus aureus.  However, it has been 
demonstrated that excessive hydrophobicity can result in increased hemolytic activity and the 
lysis of human cells.  Therefore, structure optimization is required to balance the hydrophobicity 
and cationic charge in order to maximize the polymer’s selectivity for bacterial cells over human 
cells.  Due to this need for optimization, a simple, high-throughput method for determining the 
antimicrobial and hemolytic activity of copolymers of varied hydrophobicity is desirable. 
 
Current Detection Methods 
Current methods used to detect membrane permeabilization by antimicrobial peptides and 
polymers are typically based on the efflux of fluorescent dyes, most often calcein or 
carboxyfluorescein, encapsulated in liposomes
8
 (small shells consisting of phospholipid bilayers 
often used as analytical cell mimics).  Prior to membrane permeabilization, the fluorescent signal 
is quenched.  Furthermore, because the fluorescence of these dyes is concentration-dependent, as 
more dye is released due to membrane permeabilization, an increase in fluorescence is observed
8-
9
.  These fluorescent methods, however, are disadvantageous because they require expensive 
microtiter type instrumentation for fluorescent detection and readout. 
A visual detection method for membrane permeabilization, based on the fluorescence 
emission of terbium(III) (Tb
3+
) chelated with dipicolinic acid (DPA), has also been 
documented
10
.  The binary Tb
3+
/DPA complex emits bright green fluorescence when irradiated 
with UV light, removing the need for expensive instrumentation.  In this method, unilamellar 
phospholipid vesicles encapsulate either a solution of Tb
3+
 or DPA, with the conjugate molecule 
in the external solution.  After membrane permeabilization, the interior solution is released and 
the fluorescing complex formed, resulting in a visibly fluorescent solution.  Using the 
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antimicrobial peptide alamethicin, this method was demonstrated to visually detect membrane 
permeabilization with high sensitivity and low limits of detection.  However, because the  
Tb
3+
/DPA complex excites in the UV region of the spectrum, quantitative studies for this method 
are difficult without expensive quartz microtiter plates and instrumentation. 
The methodologies currently in use for detecting membrane permeabilization are lacking a 
sensitive visual detection method that can easily be adapted for both low cost qualitative studies 
and high throughput screening of new peptides and polymers exhibiting antimicrobial behavior.   
 
Heparin Induced Thrombocytopenia (HIT) 
Heparin induced thrombocytopenia (HIT) is a side effect of the administration of the 
anticoagulant heparin that results in the development of low platelet counts about 5-10 days after 
the start of heparin therapy
11
.  In HIT, heparin complexes to platelet factor 4 (PF4), which results 
in the formation of IgG antibodies directed toward that complex by the body’s immune system.  
These IgG antibodies bind to the heparin-PF4 complexes on 
the surface of platelets in the bloodstream.  The antibody tail 
binds to the FcγIIa receptor on the surface of platelets, 
resulting in platelet activation and lysis
12
 (Figure 3)  When a 
patient is suspected of displaying complications related to 
HIT, an accurate confirmation of the diagnosis is required to 
begin the proper treatment.  However, no specific laboratory test is available and is broadly used 
for HIT diagnosis. 
 
 
Figure 3: Mechanism for plately lysis in 
HIT. Heparin and PF4 create a complex with 
IgG antibodies, which aggregate on the 
platelet surface and lead to lysis. 
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Current Detection Methods 
The most common method used for HIT diagnosis is enzyme-linked immunosorbent assay 
(ELISA), which is used to detect anti-heparin/PF4 antibodies in serum
13
.  Despite its sensitivity, 
this method lacks specificity
11
 because the immunoassay detects all circulating antibodies that 
bind to heparin-PF4 complexes and falsely identifies antibodies that do not cause HIT.   
The serotonin-release assay (SRA) is the most specific test for HIT diagnosis.  This assay 
measures platelet release/activation, as opposed to aggregation, at two heparin concentrations
15
.  
However, despite the specificity of this assay, it is used by only a few laboratories worldwide 
because it requires radioactive material and proficient human skill to be reproducible
13
.  Other 
functional methods can be used to confirm HIT, such as the particle agglutination assay and flow 
cytometry.  Both of these, however, provide variable results, and in aggregometry in particular 
the results are not standard, but depend strongly on the patient.  All three of these assays lack 
sensitivity and are often indeterminate in the first two days of HIT
13
.   
The current methods used to diagnose HIT lack either sensitivity or specificity.  As such, 
the development of a simple and sensitive diagnostic assay is needed that is potentially more 
specific for HIT antibodies. 
 
Complement Fixation 
A possible method for the detection of HIT antibodies would be an adaptation of 
complement fixation.  The complement fixation test is used to detect the presence of specific 
antibodies or antigens in serum in order to diagnose infections
16
.  The assay uses sheep red blood 
cells (sRBC) bound to anti-sRBC antibody and complement to determine whether or not a 
specific antibody is present in a patient’s serum.  If the antibody is present, addition of the 
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specific antigen will form antibody-antigen complexes that will bind to the complement in 
solution, resulting in minimal lysis of the sRBC 
complexes.  If the antibody is not present, the 
addition of antigen will not result in the 
formation of complexes, causing the 
complement to bind to sRBC complexes and 
leading to maximal sRBC lysis.  In this way, a 
test that is negative for a given antibody results 
in lysis while a positive test does not (Figure 4).  
Adaptation of the complement fixation test using liposomes in place of sRBCs may allow for a 
selective diagnostic assay for HIT. 
 
Liposomes 
In order to increase sensitivity and decrease detection limits of bioassays, the development 
of new labeling strategies that exhibit an increased signal over traditional labeling techniques has 
become an emergent trend.   One strategy to increase signal is to develop labels that are capable 
of delivering multiple tracer molecules for each binding event, through either encapsulation of 
tracer molecules or their conjugation to the exterior or a 
labeling entity.  Liposomes, first introduced in 1965
17
, 
are one such labeling method capable of delivering 
hundreds to thousands of tracer molecules per binding 
event. 
Liposomes are small spheres made of phospholipid 
Figure 4: Complement fixation test. When antibodies are not 
present, the addition of complement leads to maximum sRBC 
lysis and a negative test. In the presence of antibodies, 
complement binds to the antigen-antibody complex, resulting 
in minimal sRBC lysis and a positive test. 
Figure 5: Liposome structure.  The hydrophilic 
lipid head group is present on the outer and inner 
surface of the liposome, with a hydrophobic 
phospholipid bilayer in between. An aqueous 
volume is encapsulated in the liposome interior. 
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bilayers encapsulating a small aqueous volume, which can effectively contain any small 
hydrophilic molecule (Figure 5).  Their encapsulation abilities have made liposomes fairly 
prevalent in the pharmaceutical industry as a vehicle for drug delivery.  The liposome’s ability to 
deliver a large number of tracer molecules per each binding event has also led to the widespread 
use of these analytical reagents in both immunoassays and DNA assays
18-20
.  Furthermore, 
because liposomes can be formed using various lipid compositions, they can be used as any 
number of bacterial and mammalian cell mimics. 
In these assays, the encapsulated tracers are most often fluorophores, chemiluminescent 
dyes, and reduction/oxidation reactive species.  Upon permeabilization of the lipid bilayer, these 
species are released and can be detected using various detection methods.  Beyond encapsulation 
of the tracer molecule, tracer entities such as enzymes can be conjugated to the surface of the 
liposome shell and detected without disrupting the lipid bilayer.   
 
Enzymes and Prosthetic Groups 
A new class of potential tracer molecules is enzyme prosthetic groups, which are small 
organic molecules that bind to the active site of an enzyme.  The binding of the prosthetic group 
to an enzyme activates the enzyme by facilitating its specific functionality; without the prosthetic 
group present, the enzyme is inactive.  The protein portion of the inactive enzyme, without the 
prosthetic group, is called the apo-enzyme.  Once the prosthetic group is bound and the enzyme 
activated, it is referred to as the holo-enzyme.  The process of a prosthetic group binding to the 
apo-enzyme and activating it is called reconstitution. 
The binding of a prosthetic group to an enzyme can be either non-covalent (through 
hydrogen bonding or electrostatic interactions) or covalent (via amino acid residues), and is a 
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highly specific process resulting in tight bonding between the prosthetic group and the enzyme.  
Because of this, reconstitution can be used as a platform for detecting the concentration of a 
particular prosthetic group, and has been applied to binding and immunoassays.   
One particular assay is based on the reconstitution of apo-glucose oxidase using the 
prosthetic group flavin adenine dinucleotide (FAD)
21
.  In this homogeneous colorimetric 
immunoassay, a ligand-FAD complex (without antibody) is bound by apo-glucose oxidase; the 
activity of the reconstituted holo-glucose oxidase can be monitored through the hydrogen 
peroxide generated by the enzymatic reaction.  A prototype immunoassay for the drug 
theophylline in human serum was developed.  The binding of anti-theophylline antibodies to the 
theophylline-FAD conjugate prevented the reactivation of the apo-enzyme.  When theophylline 
was present in the sample, however, competitive binding allowed some of the FAD complex to 
reactivate the apo-enzyme, resulting in enzyme activity proportional to the amount of free 
theophylline in the sample.  Based on this, it can be seen that the amount of enzyme 
reconstitution is directly related to the concentration of free analyte in the sample. 
 
Pyrroloquinoline Quinone (PQQ) and Glucose Dehydrogenase (GDH) 
Pyrroloquinoline Quinone (PQQ) is a quinone prosthetic group 
that was discovered in 1979
22
, and is present in a variety of bacteria 
(Figure 6).  PQQ non-covalently binds as a cofactor to a large 
subgroup of quinoproteins, which are enzymes that oxidize certain 
alcohols and amines once activated by a quinine prosthetic group.  Glucose dehydrogenase 
(GDH) is one of the quinoproteins that tightly binds PQQ in its active site; once bound, GDH is 
activated and is capable of oxidizing a wide array of mono- and disaccharides into their 
Figure 6: PQQ structure. At 
neutral pH=7, PQQ has a 3- charge. 
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corresponding ketones
23
.  Specifically, holo-GDH catalyzes the oxidation of glucose into 
glucono lactone
23
. 
Upon activation, GDH forms a dimer with one 
PQQ molecule and three calcium ions (Ca
2+
) bound 
per each 50kDa enzyme monomer
24
 (Figure 7).  The 
calcium ions are required to both activate the PQQ 
prosthetic group and facilitate the dimerization of the 
GDH monomers.  Once activated, the PQQ molecules 
act as reduction and oxidation centers, with the PQQ 
molecule itself capable of repeat redox cycling.  In the presence of glucose, for example, PQQ 
undergoes a two electron reduction as a result of the oxidation of glucose to glucono lactone.   
 
Colorimetric Detection of PQQ 
The PQQ/apo-GDH reconstitution reaction has previously been adapted to a heterogeneous 
colorimetric binding assay, where PQQ-doped nanospheres are used as analytical reagents
25
.  In 
this assay, C-reactive protein (CRP) was detected using neutravidin-coated, PQQ-loaded 
poly(methyl methacrylate) nanospheres, which bind with a biotinylated CRP reporter antibody 
causing the encapsulated PQQ to be released.  The released PQQ reconstitutes the apo-GDH; 
when excess glucose and the colored redox dye 1,6-dichlorophenol indophenol (DCPIP) are 
added to the assay, a color change indicating the presence of free PQQ occurs.  In the absence of 
PQQ, the inactive GDH does not facilitate the enzymatic reaction and no color change is 
observed. 
Figure 7: Structure of GDH dimer. Ca2+ facilitates 
the dimeraztion of the enzyme. Two PQQ molecules 
are bound in each dimer, creating catalytic centers. 
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The observed color change is based on the reduction/oxidation cycle that takes place 
between PQQ, glucose, and DCPIP.  Upon lysis, PQQ is released from the nanospheres, at which 
point the free PQQ binds to the GDH present in solution, facilitated by free calcium chloride in 
solution, and the catalytic center is activated.  
Glucose is then oxidized to glucono lactone, 
reducing PQQ through a two-electron 
exchange.  The reduced PQQ in turn reduces 
the redox dye DCPIP, which changes color 
from blue in its oxidized form to colorless in its 
reduced form (Figure 8).  The optical absorbance 
assay measures the color change that occurs while 
DCPIP is reduced; a calibration curve of free PQQ 
is shown in Figure 9 to demonstrate the sensitivity 
and speed of this colorimetric assay.  Furthermore, 
the color change caused by the reduction of 
DCPIP can be observed without instrumentation, 
allowing for inexpensive and easy detection of PQQ. 
 
Statement of Research 
The main focus of this research is to further adapt the simple colorimetric detection of PQQ 
to a homogeneous microtiter plate assay for the detection of membrane permeabilization by 
antimicrobial peptides and copolymers.  PQQ-loaded liposomes are used to mimic both bacterial 
and mammalian cells depending on the lipid composition employed.  Because of this, the assay 
Figure 8: PQQ reconstitution assay concept. The two 
electron redox cycle between glucose, PQQ, and DCPIP 
results in a color change from dark blue to colorless. 
Figure 9: Dose response of free PQQ in optical assay. 
PQQ concentrations are 0.1nM, 0.25nM, 0.5nM, 1nM, 
2.5nM. 
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can be tailored to determine the antimicrobial activity of peptides and copolymers against both 
gram positive and gram negative bacteria, as well as the hemolytic activity against human cells.   
The model antimicrobial peptides 
used in this study are MSI-594 and MSI-78, 
whose sequences can be found in Table 1.  
The mechanisms for membrane 
permeabilization have been described by 
Ramamoorthy et al. elsewhere
27
.  The ability of these peptides to permeabilize membranes is 
compared to a control peptide, rat islet amyloid 
polypeptide (rIAPP), which binds to phospholipid 
membranes without disrupting most membrane 
compositions
28-29
.  Along with these peptides, the study 
focused on two series of methacrylamide copolymers, 
the PB and PH series (see Figure 2).  Within each series, polymers with varied alkyl side chain 
lengths were tested as well (Table 2).   
In this work, PQQ-loaded liposomes are incubated with an antimicrobial peptide (MSI-594 
or MSI-78), the control peptide, or a methacrylamide copolymer.  Incubation with the 
antimicrobial peptide or copolymer results in the lysis of the liposome membrane, resulting in 
the release of the encapsulated PQQ.  In the absence of peptide, or during incubation with the 
control rIAPP, the liposome membrane is not compromised and no PQQ is released.  The release 
of free PQQ is monitored by an optical absorbance assay that measures the color change due to 
the reduction of DCPIP (Figure 8).  The peptide and polymer activities are measured 
continuously for kinetic studies, as well as through a fixed endpoint assay to determine total 
21 
 
activity.  The resulting antimicrobial activity of the peptides is compared to the results of 
liposomes loaded with a fluorescent dye, while the antimicrobial and hemolytic activity of the 
copolymers are compared to the literature values provided by Kuroda et al. 
Next, the development of a novel technique for HIT diagnosis combining the colorimetric 
PQQ assay and complement fixation is discussed, taking advantage of the sensitivity afforded by 
the PQQ assay as well as the selectivity 
of complement fixation.  Ideally, this 
would involve the immobilization of 
PF4 onto the liposome surface, 
followed by the addition of heparin to 
form heparin-PF4 complexes on the 
surface of the liposomes (Figure 10).  In the presence of the anti-heparin-PF4 IgG antibodies, the 
addition of complement would cause membrane lysis and result in a positive test; without target 
antibodies present, the addition of complement should not cause lysis. This lysis will be detected 
by the reduction of DCPIP, and subsequent color change.  
Initially, a model system employing liposomes with a 2,4–dinitrophenyl (DNP) containing 
lipid is used.  The DNP molecules on the outer surface of the liposome act like the heparin-PF4 
complex on the surface of the liposomes (for the purpose of testing feasibility), which complexes 
to anti-DNP antibodies in solution.  Complement will then bind to the DNP/anti-DNP complexes 
and disrupt the lipid membrane, resulting in liposome lysis.  The addition of complement without 
anti-DNP present should not cause liposome lysis.  Preliminary progress on this new research 
project is reported, including the characterization of the liposomes and attempted proof-of-
concept experiments. 
Figure 10: HIT diagnostic assay concept. Immobilizing PF4 on the 
liposome surface would allow the heparin and anti-heparin complex to 
form on the surface, resulting in lysis in the presence of complement. 
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MATERIALS AND METHODS 
 
Materials 
PQQ was purchased from Berry & Associates (Dexter, MI).  PQQ-dependent apo-glucose 
dehydrogenase, 2-[4-(2-hydroxyethyl)-1-piperazine]ethanesulfonic acid (HEPES), and sodium 
azide were obtained from Fisher Scientific (Pittsburgh, PA).  L-α-Phosphatidylcholine (egg PC), 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE),  1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-(1’-sn-glycerol) (POPG), 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-
dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), 1,2-dioleoyl-sn-glycero-3-[phospho-
rac-(3-lysyl(1-glycerol))] (lysyl-DOPG), 1,1’2,2’-tetraoleoyl cardiolipin (CL), 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-(2,4-dinitrophenyl) (DNP PE), and 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[6-[(2,4-dinitrophenyl)amino]hexanoyl] (DNP cap PE) were 
purchased from Avanti Polar Lipids (Alabaster, AL).  Model peptides MSI-594 and MSI-78 
were synthesized as described elsewhere
27
.  Rat islet amyloid polypeptide (rIAPP) was a product 
of AnaSpec (Fremont, CA).  The PH and PB series copolymers were synthesized as described 
elsewhere
6
.  Cholesterol, sodium chloride, calcium chloride, and glucose were obtained from 
Sigma-Aldrich (St. Louis, MO), as were anti-DNP monoclonal antibodies, complement from 
human serum, and guinea pig complement sera.  All the solutions/buffers used in this work were 
prepared in the laboratory using Milli-Q grade deionized water (18.2 MΩ, Millipore Corp., 
Billerica, MA).  All experiments were performed in triplicate at room temperature. 
 
Instrumentation 
A MTX Laboratory Systems Inc. (Vienna, VA) 96-well microtiter plate reader was used 
to monitor the activity of the glucose dehydrogenase enzyme after reconstitution with PQQ 
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released from the liposomes.  The instrument utilized a 595 nm filter to record the optical 
absorbance of the test solution as a function of time for kinetic studies.  For the endpoint assay, 
an initial measurement was recorded before the addition of glucose.  Glucose was added and the 
plate was allowed to sit for 30 min.  After 30 min, a final absorbance measurement was made.  
The difference in absorbance between the two measurements was related to the peptide or 
polymer activity. 
 
Preparation of PQQ-loaded Liposomes 
Unilamellar liposomes were prepared using the freeze/thaw method followed by 
extrusion
30
.  Lipids dissolved in chloroform were combined in a glass tube.  The chloroform was 
then evaporated using a rotary evaporator, resulting in a dried lipid film on the interior of the 
glass tube.  This step was repeated after re-dissolving the lipids in chloroform.  The lipid film 
was re-dried under vacuum for 1 h.  The film was resuspended in a 250 μM PQQ solution in 
HEPES buffer (working buffer: 20 mM, pH 7.0, 290 mOsmol/kg).  The liposomes underwent 
five freeze/thaw cycles in super-cooled ethanol, after which they were extruded through a 0.22 
μm polycarbonate filter four times.  Finally, the liposomes were separated from any remaining 
free PQQ with a Sephadex G-50 medium-grade size exclusion column.   
 
Optimization of Human Cell Mimic Liposome Composition 
Liposomes composed of four different lipid compositions were prepared.  For direct 
analysis, all the liposomes were diluted to the same lipid concentration (3.18 mM).  The 
liposomes were incubated with the model peptide MSI-594 for 30 min.  After incubation, a 5 μL 
aliquot of the reaction mixture were tested in a PQQ assay containing 25 μL 50 μg/mL apo-
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GDH, 25 μL 80 mM glucose, 30 μL 0.5 mM DCPIP, and working buffer to bring the total 
volume to 100 μL.  Absorbance measurements were taken at 595 nm every 30 s for a total assay 
time of 19 min 30 s. 
 
Liposome Characterization 
Liposome concentration was determined using the Bartlett phosphate assay
31
.  The average 
liposome size was determined through dynamic light scattering (DLS) on a Nicomp 380 ZLS 
Particle Sizing System (Santa Barbara, CA).  The results of the phosphate assay and light 
scattering experiments were used to estimate the number of liposomes per unit volume.  The 
average diameter determined by DLS was used to estimate the liposome surface area, and the 
average head group surface area was assumed to be 60 Å
2
.  Therefore, for a given liposome size 
and phosphate concentration, the number of liposomes per unit volume can be calculated. 
To calculate the average amount of encapsulated PQQ, a PQQ assay using a dilute solution 
of liposomes lysed with Tween-20 surfactant was employed.  The PQQ released from this assay 
was compared to a calibration curve of free PQQ.  Five μL of diluted liposomes were tested in an 
assay containing 5 μL 50 μg/mL apo-GDH, 7.5 μL 20mM calcium chloride, 25 μL 80 mM 
glucose, 30 μL 0.5 mM DCPIP, and 10 μL 10% (wt/wt) Tween-20.  The assay was brought to 
100 μL volume using working buffer.  The determined number of PQQ molecules was divided 
by the number of liposomes in the assay, resulting in an estimated number of PQQ molecules per 
liposome. 
The stability of liposomes stored at 4°C was determined by a PQQ assay run with 
liposomes, both with and without the presence of Tween-20 surfactant, without the addition of 
calcium.  An initial stability was determined immediately after preparation and compared to 
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stability assays run each following week.  Five μL of liposomes were tested in an assay 
containing 5 μL 500 μg/mL apo-GDH, 25 μL 80 mM glucose, 30 μL 0.5 mM DCPIP, and 10 μL 
10% (wt/wt) Tween-20.  The assay was brought to 100 μL volume using working buffer.  The 
absorbance of the reaction was monitored at 595 nm every 30 s for a total assay time of 19 min 
30 s.  Any response in the absence of Tween-20 was due to the presence of free PQQ outside the 
liposome shell, indicating a loss of liposome integrity.  
 
Optimization of Liposome Concentration for Assay Detection 
Various liposome concentrations were incubated in solution with a final concentration of 4 
μM MSI-594 peptide for 30 min.  After incubation, a 5 μL aliquot of the reaction mixture was 
tested in a PQQ assay containing 25 μL 50 μg/mL apo-GDH, 25 μL 80 mM glucose, 30 μL 0.5 
mM DCPIP, and working buffer to bring the total volume to 100 μL.  Absorbance measurements 
were taken at 595 nm every 30 s for a total assay time of 19 min 30 s. 
 
Evaluation of Antimicrobial Peptide Activity 
 
Comparison with Non-Permeabilizing Peptide  
Liposomes at a total lipid concentration of 0.4 mM were added to the wells of a 96 well 
microtiter plate.  The antimicrobial or a control peptide was added in varying concentrations.  
Also added were 5 μL 500 μg/mL apo-GDH, 30 µL 0.5 mM DCPIP, 25 µL 80 mM glucose, and 
working buffer to bring the total volume to 100 µL.  The absorbance was measured 40 times at 
595 nm every 30 s, for a total assay time of 19 min 30 s.  In between measurements, the plate 
was shaken to ensure complete mixing of the assay reagents.  These experiments were conducted 
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using two liposome compositions – a 1:1:1 mole ratio of egg PC:DOPA:cholesterol and a 3:1 
mole ratio of egg PC:POPG. 
 
Endpoint Assay for Peptide Activity 
For the endpoint assay of MSI-594, the microtiter plate was prepared in the manner 
described above.  Before the addition of glucose, however, an initial absorbance measurement 
was taken.  The same concentration of glucose as described above was added, and plate was 
allowed to sit for 30 min.  At the end of 30 min, a final absorbance measurement was recorded.  
The absorbance difference between the measurements was then related to the activity of the 
peptide.  These experiments were only conducted using the 3:1 mole ratio of egg PC:POPG 
liposomes. 
 
Comparison to Fluorescent Dye-Loaded Liposomes 
Unilamellar liposomes consisting of a 1:1:1 mole ratio of egg PC:DOPA:cholesterol were 
prepared as described above using the fluorescent dye 8-hydroxypyrene-1,3,6,-trisulfonic acid 
(HPTS) instead of PQQ.  Liposomes at a total lipid concentration of 0.4 mM were added to a 
plastic cuvette.  Various concentrations of MSI-594 were added to the cuvette, and the resulting 
fluorescent signal was measured using a fluorimeter (Shimadzu; Columbia, MD), with an 
excitation wavelength of 413 nm and an emission wavelength of 510 nm. 
 
Evaluation of Synthetic Copolymer Activity 
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Effects of Hydrophobicity on Activity 
The two series of copolymers, PH and PB, each with varying fractions of side chain 
alkylation, were analyzed for membrane permeabilization activity.  The polymers were initially 
dissolved in dimethyl-sulfoxide to create 1 mg/mL solutions, which were further diluted in the 
assay.  Liposomes, at a total lipid concentration of 0.4 mM, were added to the wells of a 96 well 
microtiter plate.  Each of the copolymers were added to the wells at a final concentration of 5 
µg/mL, followed by 5 µL of 500 µg/mL of apo-GDH, 30 µL 0.5 mM DCPIP, 25 µL 80 mM 
glucose, and working buffer to bring the total volume to 100 µL.  The absorbance was measured 
40 times at 595 nm every 45 s for a total assay time of 29 min 15 s, shaking the plate in between 
measurements to ensure complete mixing of the assay reagents. These experiments were 
conducted using two liposome compositions – a 1:1:1 mole ratio of egg PC:DOPA:cholesterol 
and a 4:1 mole ratio of POPE:POPG. 
The limits of the detection for this system were determined by evaluating the dose-
responses of the most active polymers from the PH and PB series based on the lipid composition 
for egg PC, DOPA, and cholesterol lipsomes, PH51 and PB54.  The polymers were added to the 
assay in concentrations ranging from 0.5 – 4 µg/mL.  The remaining reagents were added as 
described above.  The absorbance was measured 40 times at 595 nm every 45 s for a total assay 
time of 29 min 15 s, shaking the plate in between measurements to ensure complete mixing of 
the assay reagents.   
 
Endpoint Assay for Polymer Activity 
For the endpoint assay of the copolymers, the most active polymers of the PH and PB 
series based on the two liposome compositions were used.  For the POPE/POPG liposomes, PH51 
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and PB20 were used.  For the egg PC/DOPA/ cholesterol liposomes, PH51 and PB54 were used.  
The microtiter plate was prepared in the manner described above.  Before the addition of 
glucose, however, an initial absorbance measurement was taken.  The same concentration of 
glucose as described above was added, and the plate was allowed to sit for 30 min.  At the end of 
30 min, a final absorbance measurement was recorded.  The absorbance difference between the 
measurements was then related to the activity of the polymers.   
 
Evaluation of Assay Using Gram-Positive Bacteria Liposome Mimics 
Unilamellar liposomes consisting of a 12:7:1 mole ratio of DOPG/lysyl-DOPG/cardiolipin 
(CL) were prepared as described above.  Liposomes at a total lipid concentration of 0.4 mM were 
added to the wells of a 96 well microtiter plate.  The peptides MSI-78 and MSI-594 and the 
polymers PH51 and PB20 were added to the microtiter plate at a final concentration of 5 µM.  The 
remaining reagents were added as described above.  The absorbance was measured 40 times at 
595 nm every 45 s for a total assay time of 29 min 15 s, shaking the plate in between 
measurements to ensure complete mixing of the assay reagents.  
 
Evaluation of DNP Model System 
 
Optimization of DNP Liposomes Lipid Composition 
Four lipid compositions were attempted for the development of the DNP model system for 
complement fixation detection.  Three of the compositions consisted of varying mole ratios of 
egg PC, DOPA, cholesterol, and DNP PE, while the fourth employed DNP cap PE as the DNP-
containing lipid.  Liposome concentration was determined using the Bartlett phosphate assay.  
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The stability of these liposomes, as well as the average number of encapsulated PQQ molecules, 
was determined as described above.  The viability of the composition for the DNP model system 
was tested using both the competitive binding and the complement fixation-based PQQ assays 
described below. 
 
UV-visible Absorbance of DNP Liposomes 
To determine whether or not DNP molecules were present on the surface of liposomes, 
UV-visible absorbance spectra were taken for 1:1:1 mole ratio egg PC:DOPA:cholesterol 
liposomes and 33:33:33:1 mole percent egg PC:DOPA:cholesterol:DNP PE liposomes using a 
spectrophotometer (Shimadzu; Columbia, MD).  Liposomes at a total lipid concentration of 0.4 
mM were added to a plastic cuvette in working buffer.  The spectra were obtained at wavelength 
intervals of 1 nm from 250 nm to 600 nm, using working buffer as a blank.   
 
Competitive Binding Assay 
To determine that DNP molecules present on the liposome surface can actually bind to the 
anti-DNP antibody, an adaption of the competitive binding assay based on a biotin-avidin model 
system
25
 was used.  The anti-DNP antibody was reacted with the surface of pre-activated NUNC 
amino microtiter plate wells (Fisher Scientific; Pittsburgh, PA) by adding 5 µL of 1.1 mg/mL 
anti-DNP and 95 µL of 100 mM sodium carbonate buffer (pH 9.6, conjugation buffer) to the 
wells for 90 min.  After the wells were washed with carbonate buffer, 150 µL of 40 mM 
ethanolamine were added to the wells for 1 h to cap any un-reacted sites on the surface of the 
plates.  The plates were then washed three times with carbonate buffer, and subsequently rinsed 
one time each with Tris buffer and HEPES working buffer to remove any un-reacted anti-DNP. 
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Thirty µL of either 1nM 33:33:33:1 mole percent egg PC:DOPA:cholesterol:DNP PE 
liposomes or 1:1:1 mole ratio egg PC:DOPA:cholesterol liposomes and 70 µL working buffer 
were added to control wells without anti-DNP in addition to wells that had been reacted with 
anti-DNP.  The liposomes were allowed to incubate in the microtiter plate for 45 min.  After 
incubation, the wells were washed twice with working buffer before the addition of 5 μL 500 
μg/mL apo-GDH, 25 μL 80 mM glucose, 30 μL 0.5 mM DCPIP, and 10 μL 10% (wt/wt) Tween-
20 (to lyse any bound liposomes).  The assay was brought to 100 μL volume using working 
buffer.  The absorbance of the reaction was measured 40 times at 595 nm every 60 s for a total 
assay time of 39 min, shaking the plate in between measurements to ensure complete mixing of 
the assay reagents. 
 
PQQ-Based Liposome Assay of Complement Fixation 
The complement fixation assay based on PQQ loaded liposomes was developed to contain 
three controls as well as the complement fixation assay.  The controls were comprised of 
liposomes, liposomes with anti-DNP, and liposomes with complement.  The assay included 
liposomes, anti-DNP, and complement.  Along with the DNP linked-liposomes described above, 
liposomes composed of egg PC, DOPA, and cholesterol that did not contain DNP PE were tested 
in the assay as a non-reactive control.  All of the parameters except liposome concentration, 
which was fixed at a total lipid concentration of 0.72 mM, were varied throughout the 
development of the assay.  The anti-DNP concentration ranged from a final concentration of 17 – 
250 ng/mL.  The amount of complement ranged from a final concentration of 100 ng/mL to 2.5 
μg/mL, with complement prepared from both guinea pig and human sera being used.  The assay 
was incubated prior to the addition of complement for times varying from no incubation to 1 h.  
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After incubation, 5 μL 500 μg/mL apo-GDH, 25 μL 80 mM glucose, and 30 μL 0.5 mM DCPIP 
were added to the microtiter plate, with working buffer added to bring the total volume to 100 
μL.  The absorbance was measured 40 times at 595 nm either every 45 s or every 60 s for a total 
assay time of 29 min 15 s or 39 min, respectively, shaking the plate in between measurements to 
ensure complete mixing of the assay reagents.  
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RESULTS AND DISCUSSION 
 
GDH-PQQ Reconstitution Assay 
The PQQ reconstitution assay has been previously described
25,32
.  In this assay, free PQQ is 
released from the liposomes after membrane permeabilization, resulting in the activation of apo-
GDH.  After activation, PQQ becomes a catalytic center where glucose is oxidized into glucono 
lactone, resulting in a two-electron transfer that 
reduces PQQ.  At this point, the redox dye DCPIP is 
reduced by PQQ, resulting in a color change from 
dark blue to colorless (Figure 11).  It should be 
noted that calcium was not added to the assay, as it 
has been shown that the presence of calcium 
facilitates the disruption of lipid membranes, 
generating a false positive signal for membrane 
disruption
33,34
.  This does result in a decrease in GDH activity, but, due to the homogeneous 
nature of the assay, does not completely eliminate it, with small concentrations of PQQ still 
resulting in quick and substantial changes in absorbance signal.  Because of the optical nature of 
the assay, it is advantageous in that it can yield a clear visual change in a short amount of time.  
Furthermore, no expensive or complicated instrumentation is required to detect a clear positive 
response for a species that increases membrane permeabilization. 
 
Figure 11: Assay concept. In the presence of a 
membrane-permeabilizing agent, a color change 
proportional to the concentration of peptide or 
copolymer in solution occurs. 
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Optimization of Human Cell Mimic Liposome Composition 
The results of the optimization of a liposome 
composition are shown in Figure 12.  The human cell 
mimics were based on the composition of human 
erythrocyte membranes, which are composed mainly of 
proteins and lipids, specifically cholesterol and 
phospholipids
35
.  One of the major phospholipids present 
in these membranes is phosphatidylcholine (PC).  
Because of this, each of the four compositions tested 
contained PC.   
When tested with model peptide MSI-594, it was observed that liposomes composed 
entirely of PC showed a good response to this peptide.  Liposomes composed of a 1:1 mole ratio 
of PC:DOPA, on the other hand, showed no response.  However, the addition of cholesterol to 
liposomes containing PC and DOPA resulted in an excellent response to the peptide.  Because 
the addition of 
cholesterol stabilizes 
the lipid membrane, 
and because cholesterol 
is known to be present in human cells, the liposome composition consisting of a 1:1:1 mole ratio 
of PC:DOPA:cholesterol was used for all further human cell mimic testing (Figure 13). 
 
 
 
Figure 12: Liposome composition optimization. 
Liposome response to MSI-594 for A) egg PC 
only liposomes, B) 1:1 mole ratio egg PC:DOPA 
liposomes, C) 4:4:1 mole ratio egg 
PC:DOPA:cholesterol liposomes, and D) 1:1:1 
mole ratio egg PC:DOPA: cholesterol liposomes 
Figure 13: Lipid structures for egg PC, DOPA, and cholesterol. 
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Liposome Characterization 
Liposomes composed of a 1:1:1 mole ratio of PC:DOPA:cholesterol were used for the 
determination of general liposome characteristics (Table 
3).  These liposomes were shown to be stable for at least 
three weeks when stored in the refrigerator (Figure 14).  
The PQQ-loaded liposomes were determined to be 
approximately 150 nm in diameter (Figure 15), 
containing roughly 15 molecules of PQQ per liposome. 
Liposome stability and PQQ-encapsulation data were 
obtained by running the reconstitution assay with liposomes 
in presence and absence of the detergent Tween-20.  In the 
presence of Tween-20, the lipid membrane is completely and 
irreparably destroyed, resulting in the release of all the 
encapsulated PQQ.  Because the PQQ released can be 
quantified, the number of PQQ molecules present in the 
assay can be calculated using a calibration curve 
(Figure 16).  In the absence of Tween-20 or a 
permeabilizing agent (such as peptide or polymer), the 
lipid membrane should remain intact.  If a signal is 
detected in the absence of Tween-20, it suggests the 
Figure 14: Stability of egg PC, DOPA, and 
cholesterol liposomes.  After three weeks of 
refrigerated storage, there is no significant signal 
change in unlysed liposomes, suggesting the lipid 
membrane is still intact. 
Figure 15: Average liposome size. Liposomes 
are approximately 150 nm in diameter. 
Figure 16: Free PQQ calibration curve. PQQ 
concentrations range from 0.05nM to 0.25nM. Used 
to determine total PQQ encapsulation. 
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integrity of the lipid membrane has been compromised, which can be indicative of the 
degradation of liposome stability over time.  Therefore, the liposomes were considered to be 
stable if no significant signal was observed in the absence of detergent.  As can be seen in Figure 
14, the liposomes do not show substantial leakage over a three week period, suggesting their 
good stability over this time period. 
The amount of encapsulated PQQ reported in Table 3 is much lower than would be 
expected using a 250 μM PQQ solution during liposome preparation.  The theoretical maximum 
encapsulation is calculated using the average liposome interior radius of 1x10
-5 
cm and the 
equation for the volume of a sphere, resulting in an interior volume of 4.19 attoliters.  Based on 
this volume, the maximum number of PQQ molecules that can be encapsulated is approximately 
630.  The observed PQQ encapsulation then is approximately 2% of the theoretical encapsulation 
efficiency.  This low observed encapsulation of PQQ could be due to electrostatic repulsions 
between PQQ molecules and the lipid membrane.  At neutral pH, PQQ has three negative 
charges present on each molecule.  The liposomes are also highly negatively charged due to the 
presence of DOPA lipids, each of which has a negative charge on the hydrophilic head group 
(Figure 13).  The repulsions between the negatively charged PQQ and the DOPA head groups 
could reduce the encapsulation efficiency of the liposomes. 
 
Optimization of Liposome Concentration for Assay Detection 
To determine the optimal liposome concentration for use in the assay, the concentration of 
egg PC, DOPA, and cholesterol liposomes was varied from 1 nM to 30 nM (initial 
concentration) and the assay was performed using a high concentration (16 μM) of MSI-594 
(Figure 17).  The greatest response to peptide was observed when the liposome concentration 
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was between 0.4 mM total lipid and 1 mM total lipid.  
Therefore, liposomes were used at a lipid concentration 
of 0.4 mM (corresponding to an initial concentration of 
1 nM liposomes) for all subsequent experiments. 
 
Evaluation of Antimicrobial Peptide Activity 
 
Comparison with Non-Permeabilizing Peptide  
Peptide activity was tested using two different liposome compositions.  The first 
composition, a 3:1 mole ratio of egg PC:POPG, was used as a bacterial cell mimic to determine 
the antimicrobial activity of peptides.  The 
activity of two model peptides, MSI-594 and 
MSI-78, was tested using these PC:POPG 
liposomes.  In order to establish their relative 
activities, they were compared to the inactive 
control peptide rIAPP.  The concentrations of 
these peptides were varied from 1-7 μM, and 
their membrane permeating ability was 
monitored through a 20 min kinetic absorbance assay (Figure 18).  The relative membrane 
permeabilization rates can be seen, with MSI-594 permeating at a higher rate than MSI-78 and 
rIAPP exhibiting a signal barely higher than that of liposomes in the absence of any peptide. 
In order to compare the antimicrobial activity of these peptides, the change in absorbance 
per second of each peptide was plotted (Figure 19).  Due to a varied assay response between 
Figure 17: Liposome concentration optimization. 
Liposomes ranging in concentration from 1 nM to 
30 nM were tested with a high concentration (16 
μM) of MSI-594.  The liposome concentration 
range showing highest response was from 5 nM to 
10 nM. 
Figure 18: Antimicrobial dose response for MSI-594 and MSI-
78, compared to rIAPP.  Peptide concentrations were 1 μM, 3 
μM, 5 μM, and 7 μM.  The assay selectivity over rIAPP is 
demonstrated. 
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liposome batches (based on variances in PQQ encapsulation efficiency), the assay signal for this 
data was normalized based on making the change in 
absorbance per second for PQQ release of liposomes 
incubated with 7 μM MSI-594 equal to 100% of the 
total observed slope.  The absorbance change for the 
remaining peptides and concentrations was taken as 
a fraction of this total slope.  As can be seen in 
Figure 19, the active MSI-594 and MSI-78 peptides 
show a significant increased response over the 
inactive rIAPP peptide, demonstrating the selectivity of the method for membrane-
permeabilizing peptides over inert peptides.  The ability to select for peptides with permeating 
antimicrobial activity displays the technique’s capability for peptide screening. 
Furthermore, it can be seen that both active peptides are capable of permeating membranes 
to the same extent as Tween-20.  The difference in signal observed between the two active 
peptides MSI-594 and MSI-78 is related to differences in their membrane-permeating 
mechanisms
27
.  Therefore, it can be seen that although both peptides demonstrate strong 
antimicrobial activity, MSI-594 permeates membranes at a faster rate than does MSI-78, 
especially at higher concentrations of 
peptide.  
Images of the microtiter plate 
before and after the completion of the 
kinetic assay are shown in Figure 20.  
It can be seen that wells containing the 
Figure 19: Normalized response of assay to varied 
concentrations of MSI-594, MSI-78, and rIAPP (n=3). 
The response was normalized by taking the change in 
absorbance/sec of 7 μM MSI-594 as 100% of the total 
observed slope, with each other measurement take 
Figure 20: Visual change of varying concentrations of MSI-594 and MSI-
78 compared to control peptide rIAPP before and after 20 min assay. 
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permeabilizing peptides MSI-594 and MSI-78 were colorless at the end of the 20 min assay, 
while those wells containing the inactive rIAPP were still dark blue.  This demonstrates the 
visual nature of the assay, as positive identification of membrane lysis can be determined without 
the use of instrumentation. 
Liposomes composed of a 1:1:1 mole ratio of egg PC:DOPA:cholesterol were used as 
human cell mimics to demonstrate the assay’s 
validity in monitoring the potential toxicity of 
antimicrobial peptides towards human cells.  As the 
more active peptide, the concentration of MSI-594 
was varied from 1.22-4.07 μM (Figure 21), while 
the MSI-78 concentrations were varied from 6.06-
12.11 μM (Figure 22).  Both peptides were 
compared to equivalent concentrations of 
rIAPP.  The MSI-78 data in Figure 22 is 
normalized using the same process as before, 
taking the change in absorbance per second for 
PQQ release of liposomes incubated with 12.11 
μM MSI-78 as equal to 100% of the total 
observed slope.  The MSI-594 data is not 
normalized.  It can be seen that the MSI-594 and MSI-78 peptides continue to demonstrate 
higher rates of activity over the inactive rIAPP, suggesting that the assay can also be used to 
determine the activity, and therefore the toxicity, of peptides against human cells. 
Endpoint Assay for Peptide Activity 
Figure 21: Hemolytic dose response of MSI-594 
compared to rIAPP. Assay selectivity over the control 
peptide is demonstrated. 
Figure 22: Hemolytic dose response for MSI-78 versus rIAPP. 
Assay selectivity over the control peptide is demonstrated. 
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To demonstrate the applicability of this system as a visual method for simple positive or 
negative membrane permeabilization detection, an endpoint assay was applied using MSI-594.  
In this assay, an initial absorbance measurement was 
recorded, and a final absorbance was measured 30 min 
later (Figure 23).  The overall visual nature of this assay 
is shown in Figure 24.  Once again, it can be seen that 
wells containing MSI-594 are visually distinguishable 
from those that do not, which are still dark blue.  Using 
this endpoint detection method, MSI-594 can be detected at micro-molar levels.  The limit of 
detection for this method, defined as the 
concentration of peptide equivalent to the 
absorbance change of three times the 
standard deviation of the control, was 
determined to be 396 nM.  This limit of 
detection is comparable to reported values 
of liposome-based methods of MSI-594 detection that use fluorophores as the encapsulated 
tracer molecule
27
.  Furthermore, the detection range of this method is analogous to related 
experiments performed using liposomes encapsulating the fluorescent 
dye HPTS (Figure 25), which is a molecule similar in size and charge 
to PQQ.  In these experiments, HPTS-encapsulated liposomes were 
combined with varied concentrations of MSI-594, ranging from 0.2-2.0 
Figure 23: Endpoint assay for determination of the 
antimicrobial activity of MSI-594. The detection 
limit for this system was determined to be 396nM. 
Figure 24: Visual detection of MSI-594 antimicrobial activity before 
and after 30min endpoint assay. 
Figure 25: Structure of 
fluorescent dye HPTS. 
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μM, in a plastic cuvette, and the resulting 
fluorescence was monitored (Figure 26).  The ability 
to visually detect low levels of antimicrobial 
peptides without instrumentation by using the PQQ 
loaded liposomes in place of fluorophores allows 
this system to be a useful method for the simple and 
relatively quick screening of peptide activity. 
 
Evaluation of Synthetic Copolymer Membrane Permeabilizing Activity 
 
Effects of Hydrophobicity on Activity 
The assay system was used to test the antimicrobial and hemolytic activity of two 
copolymer series, PH and PB, both with varying degrees of side chain alkylation ranging from 0 
(zero hydrophobicity) to 80 (Table 1).  Antimicrobial activity was monitored using E. coli cell 
mimics, liposomes composed of a 
4:1 mole ration of POPE:POPG 
(Figure 27), while the potential 
toxicity towards human cells 
(hemolytic activity) was determined using 1:1:1 mole ratio egg PC:DOPA:cholesterol liposomes 
as human cell mimics.   
Assay results were compared to previously described membrane disruption activities
7
, 
where it has been demonstrated that the PH series is more active overall than the PB series.  The 
reported antimicrobial activity of the PH series shows an initial decrease in activity as falkyl 
Figure 26: Detection of varied MSI-594 concentrations 
using liposomes encapsulating the fluorescent dye 
HPTS. Excitation wavelength: 413 nm. Emission 
wavelength: 510 nm. 
Figure 27: Lipid structures of POPE and POPG. 
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increased from 0.00-0.33.  However, as falkyl increased towards 0.63, the activity increases with 
overall faster kinetic responses.  For the PB series, activity is sharply decreased as falkyl increases 
from 0.00-0.54, followed by a large change in kinetic response as falkyl is increased to 0.79.   
  
 
In order to test the relative antimicrobial activity for each degree of alkylation in both 
series, 5 μg/mL of each polymer were incubated with POPE/POPG liposomes, and the activity 
was monitored via a 29 min kinetic absorbance assay (Figures 28-29).  Comparing these two 
figures, it can be seen that the PH series appears to 
be, on the whole, more active than the PB series.  A 
direct comparison of the two series can be seen in 
Figure 30.  As shown in this figure, the antimicrobial 
activity of the PH series decreases as falkyl moves 
from 0.00 to 0.33, and then increases towards 0.63.  
The antimicrobial activity of the PB series decreases 
initially as falkyl climbs to 0.54, but increases with falkyl after that.  The observed antimicrobial 
activity of these two series follows that reported in the literature
7
, demonstrating the ability of the 
Figure 28: Kinetic assay for antimicrobial activity for PH 
series with varied degrees of alkylation.  
Figure 29: Kinetic assay for antimicrobial activity for PB 
series with varied degrees of alkylation. 
Figure 30: Comparison of kinetic response of 
antimicrobial activity of the PH and PB series with 
varying falkyl values (n=3). 
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method to not only screen for antimicrobial activity, but to determine the relative activity of 
antimicrobial agents. 
Similarly, to test the polymer series for potential hemolytic toxicity, 5 μg/mL of each 
polymer were incubated with egg PC, DOPA, and cholesterol liposomes, and the activity was 
monitored through a 29 min kinetic absorbance assay 
(Figures 31-32).  As reported for the hemolytic activity, 
the PH series shows an initial decrease in activity, 
followed by a sharp increase as falkyl is increased, while 
the PB series shows a large initial decrease in activity 
with a subsequent steady increase.  From the data it can 
be seen that the PH series is more active against human 
cell mimics than is the PB series.  A direct comparison 
of the two series can be seen in Figure 33.  As shown, 
as falkyl increases, the hemolytic activity of the PH series 
initially decreases, followed by a continual increase, 
which corresponds to the reported hemolytic activity of 
PH series.  The PB series, on the other hand, shows 
fairly steady hemolytic activity, with a slight initial 
decrease followed by a slight increase in activity.  
While the PH series continues to show high membrane 
permeabilizing activity for the cholesterol-containing 
human cell mimics, demonstrating little selectivity for 
bacterial cell mimics without cholesterol, the PB series 
Figure 31: Kinetic assay for hemolytic activity for PH 
series with varied degrees of alkylation. 
Figure 32: Kinetic assay for hemolytic activity for 
PB series with varied degrees of alkylation. 
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Figure 33: Comparison of kinetic response of 
hemolytic activity of the PH and PB series with 
varying falkyl values (n=3). 
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shows significantly less activity with the cholesterol-containing liposomes than those comprised 
of POPE/POPG.  This suggests that the PB series, which contains shorter butyl-side chains than 
the hexyl-containing PH side chains, would have less toxicity towards human cells while 
demonstrating a higher selectivity for bacterial cells. 
Initial and final images of the 29 min kinetic assay for antimicrobial activity of the 
synthetic polymers are shown in Figure 34.  
These images not only show the distinctive 
color change in the presence of membrane 
permeabilizing polymeric agents as 
opposed to their absence, but also the 
degree of blue color that results from the 
relative ability of the polymers to permeate 
membranes.  Therefore, not only can this 
new method be used as a visual detection 
platform for screening antimicrobial activity of synthetic polymers, but it can also be used to 
visually detect the relative antimicrobial activity of 
these agents.   
To determine the detection limits for this 
system, the most active polymers for each series 
against the egg PC, DOPA, and cholesterol 
liposomes were used, PH51 and PB54.  Moreover, 
these polymers are good representations to use 
because their side chains are approximately 50% 
Figure 34: Visual detection of antimicrobial activity of the PH and 
PB series with varying falkyl values before and after 30min assay. 
Figure 35: Linear dose response of PH51 and PB54 
using egg PC, DOPA, and cholesterol liposomes. 
Detection limits for this system are 1.10 μg/mL (370 
nM) for PH51 and 1.47 μg/mL (490 nM) for PB54.  
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alkylated, making them somewhat, but not completely, hydrophobic.  For the dose-response 
assay, the concentration of the two polymers was varied from 0.5-4 μg/mL, and the response was 
monitored by a 29 min kinetic absorbance assay (Figure 35).  This data also supports the 
generally higher activity of the PH series over the PB series.  The limits of detection, based on 
three times the standard deviation of the control, were determined to be 1.10 μg/mL (370 nM) for 
PH51 and 1.47 μg/mL (490 nM) for PB54.  Although the system appears to be able to detect 
polymers at a concentration below 1 μg/mL, the statistical detection limit is slightly above that 
value.  However, the method is surely capable of detecting polymers at nano-molar levels.  
 
Endpoint Assay for Polymer Activity 
Along with kinetic response assays, the polymers were evaluated using the endpoint 
detection method, demonstrating the ability to adapt the system for a faster positive or negative 
screening approach.  As in the detection of MSI-
594, an initial absorbance measurement was 
recorded, followed by a final absorbance 
measurement taken 30 min later.  For each 
liposome composition, the most active polymer for 
each series was used.  For the detection of 
antimicrobial activity with POPE/POPG liposomes, PH51 and PB20 were used with 
concentrations varying from 0.5-4 μg/mL (Figure 36).  As expected, the rate of membrane 
permeation increases with concentration, with PH51 being more active than PB20.  Images of the 
microtiter plate before and after the 30 min incubation are shown in Figure 37.  It can be seen 
that wells containing polymer have undergone a significant color change as opposed to the dark 
Figure 36: Endpoint assay for detection of antimicrobial 
activity of PH51 and PB20. 
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blue control wells.  Also, the wells containing 
PH51 are considerably lighter in color than those 
containing PB20, demonstrating that the relative 
activity of the polymers can be visually detected. 
The polymers PH51 and PB54 were also 
used for the endpoint detection of hemolytic 
activity with egg PC, DOPA, and cholesterol 
liposomes, with concentrations ranging from 0.5-4 μg/mL 
(Figure 38).  As before, the PH series is demonstrated to be 
more hemolytically active than the PB series.   
 
 
 
Evaluation of Assay Using Gram-Positive Bacteria Liposome Mimics 
The bacterial cell mimics used in the previous experiments were those of gram-negative 
bacteria, specifically the POPE/POPG liposomes mimicking E. coli.  Along with bacteria that are 
considered to be gram-negative, there are gram-positive bacteria as well.  Gram-positive bacteria 
contain a high amount of peptidoglycan in their cell walls, and are stained dark blue or violet by 
Gram staining (hence the term “gram-positive”)36.  Gram-negative bacteria, on the other hand, 
have an outer-membrane that contains large amounts of lipopolysaccharides.  These bacteria do 
not retain the crystal violent dye in the Gram staining process (and are therefore “gram-
negative”) and become translucent; they can, however, be counter-stained with a red dye.  While 
there are more gram-negative bacteria species than there are gram-positive, many human-
Figure 37: Visual detection of antimicrobial activity of PH51 
and PB20 before and after 30 min endpoint assay. 
Figure 38: Endpoint assay for the detection of 
hemolytic activity of PH51 and PB54. 
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pathogenic microbes are gram-
positive, such as Staphylococcus and 
Streptococcus.  The antimicrobial 
activity of the peptides and polymers 
against gram-positive bacteria was 
assessed using S. aureus cell mimics, 
which were liposomes composed of a 12:7:1 mole ratio of DOPG:lysyl-DOPG:cardiolipin (CL) 
(Figure 39). 
The antimicrobial activity against gram-positive bacteria was determined for the peptides 
MSI-594 and MSI-78 and the polymers PH51 and PB20.  The polymers were chosen based on 
their activity against gram-negative bacteria cell 
mimics (POPE/POPG liposomes).  Liposomes 
were incubated with 5 μM of each peptide and 
polymer, and the response was monitored 
through a 29 min kinetic absorbance assay.  The 
membrane permeation results were compared to 
liposomes lysed with Tween-20 (Figure 40).  The 
assay shows a similar response to the peptides 
and polymers as it does to the detergent Tween-20, but does not show a significant response 
from the control, demonstrating that this method can be applied to the detection of antimicrobial 
agents that target gram-positive bacteria. 
 
 
Figure 39: Lipid structures of DOPG, Lysyl-DOPG, and cardiolipin. 
Figure 40: Membrane permeabilization of gram-positive 
cell mimics. The PQQ release caused by 5μM of each 
peptide and polymer was compared to that of liposomes 
lysed with Tween-20. Similar membrane lysis is 
demonstrated for the membrane-permeabilizing agents as 
is for the detergent. 
47 
 
Evaluation of DNP Model System for Complement Fixation Testing 
 
Optimization of DNP Liposomes Lipid Composition 
Four lipid compositions were tested for use in the DNP model system (Table 4).  The 
liposomes were based on the previously characterized egg PC, DOPA, and cholesterol 
liposomes, with the addition of a DNP-containing lipid (Figure 41).  The 
first lipid composition did not contain the negatively charged DOPA 
lipid because it has been observed that negatively charged liposomes are 
susceptible to lysis by complement in absence of the appropriate 
antibody
37
.  However, while these liposomes showed an initial stability 
similar to that of egg PC, DOPA, 
and cholesterol liposomes, it was 
discovered that the liposomes 
aggregated in solution after sitting for a few days (Figure 
42).  It is believed this aggregation was caused by the 
lack of any charged lipid, the presence of which results 
in repellent electrostatic forces between liposomes.  In 
order to prevent aggregation, the lipid composition was 
altered to incorporate the negatively charged DOPA 
lipid.  The liposomes composed of an equal mole ratio of 
Figure 41: Structure of DNP-
containing liposomes. The 
addition of a DNP-
containing lipid should 
result in the presence of 
DNP molecules on the 
liposome surface. 
Figure 42: Aggregation of egg PC, cholesterol 
and DNP PE liposomes in solution. 
Figure 43: Stability of 33:33:33:1 mole percent 
egg PC:DOPA:cholesterol:DNP PE liposomes. After 
three weeks of refrigerated storage, there is not 
significant signal change in unlysed liposomes, 
suggesting the lipid membrane is still intact. 
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egg PC, DOPA, and cholesterol showed increased stability over those without DOPA, with a 
stable lifetime of three weeks at 4°C (Figure 43).   
After establishing the stability of DNP-containing liposomes, a new liposome composition 
was tested taking into account the compromising effects of using a negatively charged lipid.  The 
new liposomes were synthesized using a smaller amount of DOPA, resulting in a composition of 
44:44:11:1 mole percent egg PC:cholesterol:DOPA:DNP PE.  Even with the decreased amount 
of DOPA, these liposomes did not appear to aggregate and were determined to demonstrate a 
similar stable lifetime to the previous lipid 
composition (Figure 44).  While the two liposome 
compositions exhibit similar lifetimes to each other, 
it can be seen that the amount of PQQ released is 
significantly decreased after three weeks, which was 
not observed with previous liposome compositions 
that do not contain DNP.  This decrease in PQQ 
release suggests that, while the liposome membrane is not compromised after three weeks, the 
liposomes should be utilized during that time period to ensure adequate PQQ response in any 
lysing assay.   
Finally, a fourth composition was tested which contained DNP Cap PE as the DNP-
containing lipid as opposed to DNP PE.  The DNP Cap PE lipid contains an extended linker 
chain that holds the DNP 
molecule further from the 
lipid head (Figure 45).  
Liposomes containing 
Figure 44: Stability of 44:44:11:1 egg 
PC:cholesterol:DOPA: DNP PE liposomes. After three 
weeks of refrigerated storage, there is not significant 
signal change in unlysed liposomes, suggesting the 
lipid membrane is still intact. 
Figure 45: Lipid structures of DNP PE and DNP Cap PE. The extended linker chain present 
in DNP Cap PE is highlighted in red. 
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Cap-DNP were tested based on previous observations that Cap-DNP liposomes activate the 
alternate complement pathway (ACP) for guinea pig complement better than DNP liposomes
38
.  
The Cap-DNP liposomes were determined to have a similar stable lifetime to the previous DNP 
liposomes, with little to no membrane degradation and PQQ leakage after three weeks. 
The final two liposome compositions, containing either DNP PE or DNP Cap PE, were 
determined to encapsulate approximately 30 molecules of PQQ per liposome, which is about 
double the encapsulation efficiency of liposomes without DNP.  However, these compositions 
contained a smaller mole ratio of the negatively charged DOPA lipid, which was suspected to 
reduce the encapsulation efficiency of liposomes due to repulsions between the negatively 
charged PQQ molecules and DOPA head groups.  The increase of encapsulation efficiency 
corresponding to a decreased amount of DOPA lipid seems to support this initial theory. 
 
UV-visible Absorbance of DNP liposomes 
   
 
 
To determine if DNP molecules were present on the surface of liposomes, UV-visible 
absorbance spectra were taken of liposomes with and without a DNP-containing lipid (Figures 
46 and 47).  These spectra were compared to each other to determine if the addition of DNP PE 
Figure 46: UV-visible spectrum of egg PC, DOPA, and 
cholesterol liposomes. The highlighted area shows no 
absorption between 335 nm and 385 nm. 
Figure 47: UV-visible spectrum of egg PC, DOPA, 
cholesterol, and DNP PE liposomes. The highlighted area 
shows an absorption change between 335 nm and 385 nm. 
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changed the liposome surface.  A small absorbance change can be seen between 335 nm and 385 
nm, which is highlighted on both spectra, suggesting the presence of something on the DNP 
liposome surface that is not present in liposomes that do not contain DNP.  The reported 
absorbance maximum for DNP is located at 361 nm
39
, which is within the range of the 
absorbance maximum seen in Figure 47.  While this data suggests that DNP molecules are 
present on the surface of the liposomes containing DNP PE, it is not definitive and more tests are 
needed to confirm the presence of DNP on the liposome surface. 
 
Competitive Binding Assay 
In order to confirm the DNP molecules were present on the liposome surface and available 
for binding with anti-DNP antibodies, a competitive binding assay was employed (Figure 48).  In 
this assay, amine reactive microtiter plates 
were incubated with and without the 
presence of anti-DNP antibodies.   If 
antibodies were present, they would react 
and attach to the microtiter plate.  The 
excess anti-DNP was washed from the 
plate with buffer, and the remaining un-
reacted amine sites were capped with 
ethanolamine.  At this point, liposomes 
(either composed of a 33:33:33:1 mole percent of egg PC:DOPA:cholesterol:DNP PE or 1:1:1 
mole ratio of egg PC:DOPA:cholesterol) were incubated in both the wells that contained and did 
not contain anti-DNP antibodies; after incubation, the wells were washed thoroughly to remove 
Figure 48: Competitive binding assay concept. In the presence of 
anti-DNP, DNP-containing liposomes should bind to the plate 
surface and lysis should result after the addition of Tween-20. 
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any excess liposomes.  If DNP was available for binding on the liposomes surface, the liposomes 
should remain bound to the anti-DNP on the surface of the microtiter plate after washing.  If 
DNP was not available, no liposomes should remain in the well.  Testing liposomes without 
DNP acted as a control to ensure that it is the DNP molecules on the liposome surface, and not 
the liposomes themselves, reacting with the antibody.  The detergent Tween-20 was added to all 
wells to lyse any liposome present, resulting in a release of PQQ.  
The results of the binding assay are shown in Figure 49.  It can be seen that a signal is 
observed only in the case of the DNP 
liposomes in the presence of anti-DNP 
antibodies, with none of the controls resulting 
in surface bound liposomes reacting with the 
antibodies on the microtiter plate.  Based on 
this, it can be concluded that the DNP 
molecules are not only present on the 
liposome surface, but are available and 
capable of binding with the anti-DNP antibodies.  Furthermore, these results demonstrate that the 
anti-DNP antibodies are interacting with the DNP molecules on the liposome surface, and not the 
lipid membrane, establishing the selectivity of the antibodies for the DNP molecules over other 
reagents in solution. 
 
Complement Fixation Using DNP-Liposomes Loaded with PQQ 
The long-term goal of this project was to develop a diagnostic assay for HIT that combines 
the selectivity of complement fixation with the sensitivity of the PQQ reconstitution assay.  A 
Figure 49: Competitive binding assay of egg PC, DOPA, and 
cholesterol liposomes with and without DNP PE. A signal is 
observed only when DNP-containing liposomes are in the 
presence of anti-DNP. 
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model system using liposomes composed of a DNP-containing lipid that should interact with 
anti-DNP antibodies was investigated first.  Liposomes have previously been reported to interact 
with complement after antibody fixation at the surface
40
, allowing the assay to retain the 
selectivity of the complement fixation test.  The DNP molecules on the surface of PQQ-
encapsulated liposomes should complex with both anti-DNP antibodies and complement in 
solution, resulting in membrane lysis and the release of PQQ. 
Three liposome compositions (excluding the composition without DOPA) were tested, 
along with two types of complement for release of PQQ.  The concentrations of antibody and 
complement in assay solution, as well as the time reagents were allowed to incubate, were 
varied.  Liposomes composed of egg PC, DOPA, and cholesterol, without a DNP-containing 
lipid, were tested as well to determine if antibody and complement interacted with the lipid 
membrane in the absence of DNP. 
Complement from human sera was initially used based on availability.  However, the 
switch to guinea pig complement was made when no assay response was detected with the 
human sera complement.  Furthermore, it has been previously reported that guinea pig ACP 
reacts more efficiently with DNP-Cap-liposomes than does human ACP
38
.   
The addition of anti-DNP antibodies and complement, both individually and 
simultaneously, to liposomes composed of a 1:1:1 mole ratio of egg PC:DOPA:cholesterol 
without a DNP-containing lipid did not result in liposome membrane lysis.  The inability of the 
antibody and complement to complex and lyse liposomes without DNP demonstrates that the 
lipid membrane is not interacting with the complement in the absence of surface DNP molecules. 
The optimization of the DNP model system was based on the variations in lipid 
composition, complement source, concentrations of antibody and complement, and length of 
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incubation time.  However, a response to PQQ release based on the interaction between anti-
DNP antibodies and complement with the DNP molecules on the liposome surface was not 
detected for this system.  A representative result of the kinetic response for the DNP model 
system assay is shown in Figure 50.  It can 
be seen that no significant difference is 
present between the controls (which should 
not result in membrane permeabilization) 
and the assay wells containing DNP 
liposomes, anti-DNP, and complement 
(which should complex and facilitate the 
release of PQQ).  It was therefore concluded 
that the optimization of the DNP model system based on these parameters did not result in any 
assay response, and proof-of-concept for this system was not attained. 
Despite the unsuccessful attempt to optimize the DNP model system to detect complement 
fixation, there are remaining variables to be investigated.  The liposome compositions containing 
egg PC, DOPA, and cholesterol were based on previous work with the PQQ assay system; 
however, they do not coincide with the lipid compositions reported in the literature that is used 
for complement tests
38,40-41
.  Using a previously proven lipid composition for DNP/anti-DNP 
complement fixation may result in better interactions between DNP molecules, antibodies, and 
complement, leading to the expected assay response.  Similarly, removing the negatively charged 
lipid DOPA, which is known to facilitate liposome activation by complement without antibody 
present, from the composition and instead incorporating a positively charged lipid (to maintain 
aggregation prevention) may yield better results.  Furthermore, dramatically increasing the 
Figure 50: Representative spectrum of the kinetic response for 
the DNP model system. It can be seen that the response from the 
assay which should result in liposome lysis is not significantly 
different from the control responses. 
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amount of DNP lipid within the liposome may lead to more interactions between DNP molecules 
and anti-DNP antibodies.  However, with this increase it may be necessary to optimize the 
amount of DNP lipid to avoid steric effects.  It is also possible that the small size of the 
liposomes (approximately 150 nm in diameter) may be causing steric effects that are preventing 
the DNP, anti-DNP, and complement complex from forming the required ternary complex.  
Increasing the liposome size may help to reduce any steric hindrances that may be present and 
result in greater antibody and complement interaction with the DNP molecules on the liposome 
surface.   Although the DNP model system has not yet resulted in the assay response expected, 
there are still many variables that can be investigated to further attempt the optimization of this 
system. 
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CONCLUSIONS 
 
The GDH reconstitution assay using PQQ-encapsulated liposomes as cell mimics is a 
simple and sensitive platform for the detection of membrane permeabilization by antimicrobial 
agents such as peptides and synthetic copolymers.  The method demonstrated high selectivity for 
the active peptides MSI-594 and MSI-78 over the inactive control peptide rIAPP, allowing it to 
be a simple method to determine the relative antimicrobial activity of different peptides.  Using a 
30 min endpoint detection assay, active peptide MSI-594 can be detected at concentrations as 
low as 396 nM, which is comparable to the sensitivity of current detection methods that use 
fluorescent dye-loaded liposomes.  Furthermore, the optical nature of the assay allows for a 
visual detection of membrane lysis, allowing the simple screening of peptide activity without the 
use of expensive and complicated instrumentation. 
The antimicrobial activity of the PH and PB polymer series, each with varying degrees of 
side chain alkylation, was investigated as well.  The effect of hydrophobicity on the 
antimicrobial activity of the polymer was easily determined by this method, with PH51 and PB20 
demonstrating the highest activity for each series.  Similarly, the effect of hydrophobicity on the 
hemolytic activity of both polymer series was determined as well, with PH51 and PB54 exhibiting 
the most potential toxicity towards mammalian cells.  Similar to the peptide detection, the assay 
method is capable of detecting copolymers at nano-molar levels, with limits of detection of 370 
nM for PH51 and 490 nM for PB54.   
Along with the ability to detect membrane permeabilization in both mammalian and gram 
negative bacteria cell mimics, the new assay method was employed to detect the permeation of 
gram positive bacteria cell mimic membranes as well.  This method can therefore be used to 
detect antimicrobial agents that target both gram positive and gram negative bacteria, as well as 
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determine the potential toxicity of those agents against mammalian cells.  This method should be 
an attractive tool for the determination of antimicrobial activity of both new antimicrobial 
entities and already known species such as amyloid peptides or toxins. 
While proof-of-concept and optimization of the DNP model system for complement 
fixation (aimed at developing a new type of HIT detection method) was not achieved, progress 
was made in the direction of system optimization.  It was determined that DNP molecules are 
present on the surface of the liposomes and are capable of binding with anti-DNP antibodies.  It 
was also determined that the antibodies are interacting with the DNP molecules themselves, and 
not the lipid membrane of the liposomes, establishing the selectivity of the antibodies for DNP 
molecules.  Although the effort to optimize the DNP model system was not successful, there are 
still several research directions to pursue to demonstrate the concept of the proposed system. 
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